Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

Kapoor, Avnish, Yao, Wantong, Ying, Haoqiang, Hua, Sujun, Liewen, Alison, Wang, Qiuyun, Zhong, Yi, Wu, Chang-Jiun +22 more·2014·Cell
DOI 10.1016/j.cell.2014.06.003

Cited by (717)

Items 301–400 of 717

  1. Mechanically stressed cancer microenvironment: Role in pancreatic cancer progression
    Matthew Kyle Hadden, Anubhav Mittal, Jaswinder Singh Samra, Hala Zreiqat, Sumit Sahni, Yogambha Ramaswamy · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  2. A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models
    Zheng Zhong, Nathan Harmston, Kris C. Wood, Babita Madan, David M. Virshup · 2022 · Journal of Clinical Investigation
  3. KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)
    Rafael Rosell, Jordi Codony‐Servat, Jessica González, Mariacarmela Santarpía, Anisha S Jain, Chandan Shivamallu, Yu Wang, Ana A. Giménez-Capitán, Miguel Ángel Molina‐Vila, Jonas A. Nilsson et al. · 2023 · Critical Reviews in Oncology/Hematology
  4. Organ Size Control Is Dominant over Rb Family Inactivation to Restrict Proliferation In Vivo
    Ursula Ehmer, Anne‐Flore Zmoos, Raymond K. Auerbach, Dedeepya Vaka, Atul Janardhan Butte, Mark A. Kay, Julien Sage · 2014 · Cell Reports
  5. Context-dependent transcriptional regulations of YAP/TAZ in cancer
    Yibo Guo, Juan Luo, Hailin Zou, Chenxin Liu, Liang Deng, Peng Li · 2021 · Cancer Letters
  6. Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular
    Ou Li, Li Li, Yunru Sheng, Kun Ke, Jianzhang Wu, Yiping Mou, Mingyang Liu, Weiwei Jin · 2023 · Cancer Letters
  7. Metabolic Features of Cancer Treatment Resistance
    Andrea Viale, Giulio Francesco Draetta · 2016 · Recent results in cancer research/Recent Results in Cancer Research
  8. miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP
    Min Ho Choe, Yoon Yina, Joon Kim, Sang-Gu Hwang, Young-Hoon Han, Jae‐Sung Kim · 2018 · Cell Death and Disease
  9. Regulation of Hippo signaling pathway in cancer: A MicroRNA perspective
    Priyanka Samji, Manoj Kumar Rajendran, Vidya P. Warrier, Akshayaa Ganesh, Devarajan Karunagaran · 2020 · Cellular Signalling
  10. Hippo Pathway in Regulating Drug Resistance of Glioblastoma
    Giacomo Casati, Laura Giunti, Anna Lisa Iorio, Arianna Marturano, Luisa Galli, Iacopo Sardi · 2021 · International Journal of Molecular Sciences
  11. Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium
    Sharon E. Johnatty, Jonathan P. Tyrer, Siddhartha Kar, Jonathan Beesley, Yi Lu, Bo Gao, Peter Andreas Fasching, Alexander Hein, Arif Bülent Ekici, Matthias W. Beckmann et al. · 2015 · Clinical Cancer Research
  12. The Tumor Suppressor BAP1 Regulates the Hippo Pathway in Pancreatic Ductal Adenocarcinoma
    Ho-June Lee, Trang Pham, Matthew T. Chang, Dwight Barnes, Allen G. Cai, Rajkumar Noubade, Klára Tótpál, Xu Chen, Christopher Tran, Thijs J. Hagenbeek et al. · 2020 · Cancer Research
  13. Disease Modeling on Tumor Organoids Implicates AURKA as a Therapeutic Target in Liver Metastatic Colorectal Cancer
    Sophie Luise Boos, Leon P. Loevenich, Sebastian Vosberg, Thomas Engleitner, Rupert Öllinger, Jörg Kumbrink, Matjaž Rokavec, Marlies Michl, Philipp A. Greif, Andreas Jung et al. · 2021 · Cellular and Molecular Gastroenterology and Hepatology
  14. The Hippo signal transduction pathway in soft tissue sarcomas
    Abdalla D. Mohamed, Annie Tremblay, Graeme I. Murray, Henning Wackerhage · 2015 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  15. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma
    Hui-Wen Lue, Brook C. Cole, Soumya Alige Mahabala Rao, Jennifer Podolak, Ahna Van Gaest, Carly J. King, Christopher A. Eide, Beth Wilmot, Changhui Xue, Paul T. Spellman et al. · 2015 · Oncotarget
  16. Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets
    Matthias Drosten, Carmen E. Guerra, Mariano Barbacid · 2017 · Cold Spring Harbor Perspectives in Medicine
  17. RAS degraders: The new frontier for RAS-driven cancers
    Taylor E. Escher, K.J.F. Satchell · 2023 · Molecular Therapy
  18. Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer
    Ofra Novoplansky, Avital Beeri Shnerb, Divyasree Marripati, Sankar Jagadeeshan, Raghda Abu Shareb, Cristina Conde‐López, Jonathan Zorea, Manu Prasad, Talal Ben Lulu, Ksenia M. Yegodayev et al. · 2023 · Molecular Oncology
  19. An Updated Understanding of the Role of YAP in Driving Oncogenic Responses
    Giampaolo Morciano, Bianca Vezzani, Sonia Missiroli, Caterina Boncompagni, Paolo Pinton, Carlotta Giorgi · 2021 · Cancers
  20. Dasatinib sensitises KRAS -mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity
    Rao, Guanhua, Kim, In-kyu, Conforti, Fabio, Liu, Jing, Zhang, Yu-Wen, Giaccone, Giuseppe · 2018 · European Journal of Cancer
  21. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies
    Bingliang Fang · 2015 · Acta Biochimica et Biophysica Sinica
  22. Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer
    Rui Yan, JianJian Li, Ying Zhou, Yao Li, Ruya Sun, Ying Xu, Yang Ge, Guangyu An · 2019 · Life Sciences
  23. Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
    Friederike Inga Nollmann, Dietrich Alexander Ruess · 2020 · Biomedicines
  24. The S-phase-induced lncRNA SUNO1 promotes cell proliferation by controlling YAP1/Hippo signaling pathway
    Qinyu Hao, Xinying Zong, Qinyu Sun, Yo-Chuen Lin, You Jin Song, Seyedsasan Hashemikhabir, Rosaline Y.C. Hsu, Mohammad Zahid Kamran, Ritu Chaudhary, Vidisha Tripathi et al. · 2020 · eLife
  25. The role of RAS oncogenes in controlling epithelial mechanics
    Agata Nyga, Sushila Ganguli, Helen K. Matthews, Buzz Baum · 2022 · Trends in Cell Biology
  26. Targeting KRAS in PDAC: A New Way to Cure It?
    Qianyu He, Zuojia Liu, Jin Wang · 2022 · Cancers
  27. Metabolism remodeling in pancreatic ductal adenocarcinoma
    Jintao Li, Yi-Ping Wang, Miao Yin, Qun‐Ying Lei · 2019 · Cell Stress
  28. Targeting the Hippo Pathway in Gastric Cancer and Other Malignancies in the Digestive System: From Bench to Bedside
    Xiaoli Liu, Yifei Wang, Bonan Chen, Wai Nok Chan, Chun Wai Mui, Alvin H.K. Cheung, Jinglin Zhang, Kit Yee Wong, Jun Qing Yu, Wei Kang et al. · 2022 · Biomedicines
  29. Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA
    Christoph Neumayer, Denise Ng, Caroline S. Jiang, Adam Qureshi, Gadi Lalazar, ROGER D. VAUGHAN, Sanford M. Simon · 2022 · Clinical Cancer Research
  30. USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer
    Hou, Pingping, Ma, Xingdi, Yang, Zecheng, Zhang, Qiang, Wu, Chang-Jiun, Li, Jun, Tan, Lin, Yao, Wantong, Yan, Liang, Zhou, Xin et al. · 2021 · Genes & Development
  31. Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes?
    Katherine Eason, Anguraj Sadanandam · 2016 · Cancer Research
  32. Pancreas lineage allocation and specification are regulated by sphingosine-1-phosphate signalling
    Ioannis Serafimidis, E. Rodríguez-Aznar, M. Lesche, Kazuaki Yoshioka, Y. Takuwa, A. Dahl, D. Pan, A. Gavalas · 2017 · PLoS Biology
  33. MEK nuclear localization promotes YAP stability via sequestering β-TrCP in KRAS mutant cancer cells
    Huanji Xu, Sheng Zhou, Hongwei Xia, Huangfei Yu, Qiulin Tang, Feng Bi · 2019 · Cell Death and Differentiation
  34. Role of Hedgehog and Hippo signaling pathways in cancer: A special focus on non-coding RNAs
    Uttam Sharma, Hardeep Singh Tuli, Vivek Uttam, Renuka Choudhary, Bunty Sharma, Ujjawal Sharma, Hridayesh Prakash, Aklank Jain · 2022 · Pharmacological Research
  35. MARK2/MARK3 Kinases Are Catalytic Codependencies of YAP/TAZ in Human Cancer
    Olaf Klingbeil, Damianos S. Skopelitis, Claudia Tonelli, Toyoki Yoshimoto, Aktan Alpsoy, Maria C. Panepinto, Francesca Minicozzi, Joseph R. Merrill, Amanda M. Cafiero, Disha Aggarwal et al. · 2024 · Cancer Discovery
  36. Inhibition of yes‐associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model
    Ping‐Chih Hsu, Jinbai Miao, Zhen Huang, Yi‐Lin Yang, Zhidong Xu, Joanna You, Yuyuan Dai, Che‐Chung Yeh, Geraldine Chan, Shu Liu et al. · 2018 · Journal of Cellular and Molecular Medicine
  37. In vitro establishment of expanded-potential stem cells from mouse pre-implantation embryos or embryonic stem cells
    Jian Ping Yang, David John Ryan, Guocheng Lan, Xiangang Zou, Pentao Liu · 2019 · Nature Protocols
  38. Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine model
    Ping‐Chih Hsu, Bo Tian, Yi‐Lin Yang, Yucheng Wang, Shu Liu, Anatoly Urisman, Cheng‐Ta Yang, Zhidong Xu, David M. Jablons, Liang You · 2019 · Oncology Reports
  39. LATS1/2 suppress NFκB and aberrant EMT initiation to permit pancreatic progenitor differentiation
    Caitlin M Braitsch, D. B. Azizoglu, Yadanar Htike, H. Barlow, Ulrike Schnell, C. Chaney, Thomas J. Carroll, B. Stanger, O. Cleaver · 2019 · PLoS Biology
  40. MK5 Regulates YAP Stability and Is a Molecular Target in YAP-Driven Cancers
    Jimyung Seo, Min Hwan Kim, Hyowon Hong, Hyunsoo Cho, Seongyeol Park, Sang Kyum Kim, Joon Kim · 2019 · Cancer Research
  41. Overexpressed WDR3 induces the activation of Hippo pathway by interacting with GATA4 in pancreatic cancer
    Wenjie Su, Shikai Zhu, Kai Chen, Hongji Yang, Mingwu Tian, Qiang Fu, Ganggang Shi, Shijian Feng, Dianyun Ren, Xin Jin et al. · 2021 · Journal of Experimental & Clinical Cancer Research
  42. Hippo-YAP/TAZ signaling in breast cancer: Reciprocal regulation of microRNAs and implications in precision medicine
    Farzad Sadri, Seyede Fatemeh Hosseini, Zohreh Rezaei, Mohammad Fereidouni · 2023 · Genes & Diseases
  43. H-ras Inhibits the Hippo Pathway by Promoting Mst1/Mst2 Heterodimerization
    Sonali Jalan Rawat, Daniela Araiza‐Olivera, Luis E. Arias‐Romero, Olga Villamar Cruz, Tatiana Y. Prudnikova, Heinrich Röder, Jonathan Chernoff · 2016 · Current Biology
  44. YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis
    Yang, Wang, Zhang, Ming, Zhang, Tian-Xing, Liu, Jia-Hui, Hao, Man-Wei, Yan, Xu, Gao, Haicheng, Lei, Qun-Ying, Cui, Jiuwei, Zhou, Xin · 2024 · JCI Insight
  45. Cooperation between the Hippo and MAPK pathway activation drives acquired resistance to TEAD inhibition
    Sayantanee Paul, Thijs J. Hagenbeek, Julien Tremblay, Vasumathi Kameswaran, Christy C. Ong, Chad Liu, Alissa D. Guarnaccia, James A. Mondo, Peter Hsu, Noelyn M. Kljavin et al. · 2025 · Nature Communications
  46. A first-in-class EGFR-directed KRAS G12V selective inhibitor
    Lyla J. Stanland, Hayden P. Huggins, Snehasudha S Sahoo, Alessandro Porrello, Yogitha S. Chareddy, Salma H. Azam, Jillian L. Perry, Pradeep S. Pallan, Kristina Marinak Whately, Lincy Edatt et al. · 2025 · Cancer Cell
  47. RASSF5: An MST activator and tumor suppressor in vivo but opposite in vitro
    Tsung-Jen Liao, Chung‐Jung Tsai, Hyunbum Jang, David Fushman, Ruth Nussinov · 2016 · Current Opinion in Structural Biology
  48. Verteporfin induces lipid peroxidation and ferroptosis in pancreatic cancer cells
    Wei Jie Zhou, Adrian Lim, Omer Hany Miligy Elmadbouh, Mouad Edderkaoui, Arsen Osipov, Angela Mathison, Raul A. Urrutia, Tao Liu, Qiang Wang, Stephen Jacob Pandol · 2024 · Free Radical Biology and Medicine
  49. Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?
    Sayantanee Paul, Jessica Sims, Trang Pham, Anwesha Dey · 2024 · Trends in cancer
  50. K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?
    Ruth Nussinov, Serena Muratcioğlu, Chung‐Jung Tsai, Hyunbum Jang, Attila Gürsoy, Özlem Keskin · 2015 · Expert Opinion on Therapeutic Targets
  51. MicroRNA-1285 inhibits malignant biological behaviors of human pancreatic cancer cells by negative regulation of YAP1
    He Huang, G. Xiong, Pan Shen, Z Cao, L. Zheng, Tianzhu Zhang, Yingying Zhao · 2017 · Neoplasma
  52. Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance
    Enrique Rozengurt, Guido Eibl · 2021 · Cancers
  53. The role of YAP1 in survival prediction, immune modulation, and drug response: A pan-cancer perspective
    Xueqing Hu, Yingru Zhang, Hao Nao Yu, Yiyang Zhao, Xiaoting Sun, Qi Li, Yan Wang · 2022 · Frontiers in Immunology
  54. DUB3 Deubiquitylating Enzymes Regulate Hippo Pathway Activity by Regulating the Stability of ITCH, LATS and AMOT Proteins
    Thanh Nguyen, Jan‐Michael Kugler, Stephen Michael Cohen · 2017 · PLoS ONE
  55. CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer
    Prahallad, Anirudh, Weiss, Andreas, Voshol, Hans, Kerr, Grainne, Sprouffske, Kathleen, Yuan, Tina, Ruddy, David, Meistertzheim, Morgane, Kazic-Legueux, Malika, Kottarathil, Tina et al. · 2023 · Cancer Research
  56. Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors
    María E.R. García-Rendueles, Gnana Prakasam Krishnamoorthy, Mahesh Saqcena, Adrián Acuña-Ruíz, Giovanna Revilla, Elisa de Stanchina, Jeffrey A. Knauf, Rona Lester, Bin Xu, Ronald A. Ghossein et al. · 2022 · Molecular Cancer
  57. Molecular and Phenotypic Profiling for Precision Medicine in Pancreatic Cancer: Current Advances and Future Perspectives
    Koji Miyabayashi, Hayato Nakagawa, Kazuhiko Koike · 2021 · Frontiers in Oncology
  58. Metabolic landscapes in sarcomas
    Richard MIALLOT, Franck Galland, Virginie Millet, Jean‐Yves Blay, Philippe Naquet · 2021 · Journal of Hematology & Oncology
  59. Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1
    Yan Han, Chih-Chieh Yu, Stuart A. Fine, Ayman Lee Youssof, Yeran Yang, Jun Yan, Dillon C. Karg, Edwin C. Cheung, Richard A. Friedman, Haoqiang Ying et al. · 2021 · Oncogene
  60. Integration of Transcriptome and Methylome Highlights the Roles of Cell Cycle and Hippo Signaling Pathway in Flatfish Sexual Size Dimorphism
    Na Wang, Qian Yang, Jialin Wang, Rui Shi, Ming Li, Jin Gao, Wenteng Xu, Yingming Yang, Yadong Chen, Songlin Chen · 2021 · Frontiers in Cell and Developmental Biology
  61. Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
    Akira Ooki, Hiroki Osumi, Keisho Chìn, Masayuki Watanabe, Kensei Yamaguchi · 2023 · Therapeutic Advances in Medical Oncology
  62. The YAP1–NMU Axis Is Associated with Pancreatic Cancer Progression and Poor Outcome: Identification of a Novel Diagnostic Biomarker and Therapeutic Target
    Wonbeak Yoo, Jaemin Lee, Eunsung Jun, Kyung Hee Noh, Sangmin Lee, Dana Jung, Kwang Hwa Jung, Ji-Su Kim, Yun-Yong Park, Song Cheol Kim et al. · 2019 · Cancers
  63. Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
    Yuta Adachi, Ryo Kimura, Kentaro Hirade, Hiromichi Ebi · 2021 · Cancers
  64. Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer
    Alice Cortesi, Francesco Gandolfi, Fabiana Arco, Pierluigi Di Chiaro, Emanuele Valli, Sara Polletti, Roberta Noberini, Francesco Gualdrini, Sergio Attanasio, Francesca Citron et al. · 2024 · Science Advances
  65. Retracted: Lovastatin Inhibits RhoA to Suppress Canonical Wnt/β-Catenin Signaling and Alternative Wnt-YAP/TAZ Signaling in Colon Cancer
    Yi Xiao, Qin Liu, Nanyin Peng, Yuzhang Li, Danyang Qiu, Tianlun Yang, Richard D. Kang, Ahsan Usmani, Efosa Amadasu, Cesar V. Borlongan et al. · 2022 · Cell Transplantation · Retracted
  66. The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
    Rodrigo Entrialgo‐Cadierno, Cristina Cueto‐Ureña, Connor Welch, Iker Feliu, Irati Macaya, Laura Vera, Xabier Morales, Sandra Vietti Michelina, Pietro Scaparone, Inés López et al. · 2023 · Molecular Cancer
  67. Knockdown of SOX18 inhibits the proliferation, migration and invasion of hepatocellular carcinoma cells
    GUIMING WANG, Zhigang Wei, Hongyan Jia, Wenbo Zhao, Gaochao Yang, Haoliang Zhao · 2015 · Oncology Reports
  68. Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer
    Jincheng Han, Jiaqian Xu, Yonghong Liu, Shaoheng Liang, Kyle A. LaBella, Deepavali Chakravarti, Denise J. Spring, Yan Xia, Ronald Anthony DePinho · 2023 · Genes & Development
  69. Development of microRNA-based therapy for pancreatic cancer
    Andrew T. Fesler, Jingfang Ju · 2019 · Journal of Pancreatology
  70. YAP Activity is Not Associated with Survival of Uveal Melanoma Patients and Cell Lines
    Yong Joon Kim, Sung Chul Lee, Sung Eun Kim, Sang Kyum Kim, Sang Kyum Kim, Christopher Seungkyu Lee · 2020 · Scientific Reports
  71. Deregulation of Transcription Factor Networks Driving Cell Plasticity and Metastasis in Pancreatic Cancer
    Ruthger van Roey, Thomas Brabletz, Marc P. Stemmler, Isabell Armstark · 2021 · Frontiers in Cell and Developmental Biology
  72. FGF8 promotes cell proliferation and resistance to EGFR inhibitors via upregulation of EGFR in human hepatocellular carcinoma cells
    Yuanmin Pei, Xueling Sun, Xiwei Guo, Hua-shan Yin, Le Wang, Fugu Tian, Hongxi Jing, Xiaobo Liang, Jun Xu, Pengcheng Shi · 2017 · Oncology Reports
  73. Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer
    Laurence A. Booth, Andrew Stewart Poklepovic, Paul Dent · 2020 · Biochemical Pharmacology
  74. Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to Adapt
    Noritaka Tanaka, Hiromichi Ebi · 2024 · Cancer Science
  75. Changing the course of pancreatic cancer – Focus on recent translational advances
    Milind M. Javle, Talia Golan, Anirban Maitra · 2016 · Cancer Treatment Reviews
  76. Ubiquitination‑deubiquitination in the Hippo signaling pathway (Review)
    Yanting Liu, Jun Deng · 2019 · Oncology Reports
  77. Increasing cancer permeability by photodynamic priming: from microenvironment to mechanotransduction signaling
    Nazareth Milagros Carigga Gutierrez, Núria Pujol‐Solé, Qendresa Arifi, Jean‐Luc Coll, Tristan Le Clainche, Mans Broekgaarden · 2022 · Cancer and Metastasis Reviews
  78. The dynamic mechanism of RASSF5 and MST kinase activation by Ras
    Tsung-Jen Liao, Hyunbum Jang, Chung‐Jung Tsai, David Fushman, Ruth Nussinov · 2017 · Physical Chemistry Chemical Physics
  79. Yes-Associated Protein 1 Plays Major Roles in Pancreatic Stellate Cell Activation and Fibroinflammatory Responses
    Cheng Hu, Jiayue Yang, Hsin‐Yuan Su, Richard T. Waldron, Mengmeng Zhi, Ling Li, Qing Xia, Stephen Jacob Pandol, Aurelia Lugea · 2019 · Frontiers in Physiology
  80. Predicting Human Genetic Interactions from Cancer Genome Evolution
    Xiaowen Lu, Wout Megchelenbrink, Richard A. Notebaart, Martijn A. Huynen · 2015 · PLoS ONE
  81. TEAD Proteins Associate With DNA Repair Proteins to Facilitate Cellular Recovery From DNA Damage
    Calses, Philamer C., Pham, Victoria C., Guarnaccia, Alissa D., Choi, Meena, Verschueren, Erik, Bakker, Sietske T., Pham, Trang H., Hinkle, Trent, Liu, Chad, Chang, Matthew T. et al. · 2023 · Molecular & Cellular Proteomics
  82. Natural compounds targeting YAP/TAZ axis in cancer: Current state of art and challenges
    Aviral Kumar, Bandari BharathwajChetty, Mukesh Kumar Manickasamy, Jyothsna Unnikrishnan, Mohammed Saeed Alqahtani, Muhammad Abbas, Hassan Ali Almubarak, Gautam Sethi, Ajaikumar Bahulayan Kunnumakkara · 2024 · Pharmacological Research
  83. Advances in the Genetics and Biology of Pancreatic Cancer
    Andrew J. Aguirre, Eric Andrew Collisson · 2017 · The Cancer Journal
  84. Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting
    Pablo Hernández-Camarero, Elena López‐Ruiz, Carmen Griñán‐Lisón, María Ángel García, Carlos Chocarro‐Wrona, Juan Antonio Marchal, Julian Kenyon, Macarena Perán · 2019 · Scientific Reports
  85. A positive feedback regulation between long noncoding RNA SNHG1 and YAP1 modulates growth and metastasis in laryngeal squamous cell carcinoma.
    Ling Gao, Hua Cao, Xiulian Cheng · 2018 · Europe PMC (PubMed Central) · Retracted
  86. Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib
    Paul Dent, Laurence A. Booth, Andrew Stewart Poklepovic, Daniel D. Von Hoff, Jennifer Martinez, Yong Zhou, John F. Hancock · 2021 · Biochemical Pharmacology
  87. Hypoxia induces oncogene yes-associated protein 1 nuclear translocation to promote pancreatic ductal adenocarcinoma invasion via epithelial–mesenchymal transition
    Honglong Wei, Zongzhen Xu, Feng Liu, Fuhai Wang, Xin Wang, Xueying Sun, Jie Li · 2017 · Tumor Biology
  88. Initiation of human mammary cell tumorigenesis by mutant KRAS requires YAP inactivation
    Sylvain Lefort, Susanna Tan, Sneha Balani, Bo Rafn, Davide Pellacani, Martin Hirst, Poul H. B. Sorensen, Connie J. Eaves · 2019 · Oncogene
  89. The WW domains dictate isoform-specific regulation of YAP1 stability and pancreatic cancer cell malignancy
    Qiang Guo, Meiyu Quan, Jinglai Dong, Jing Bai, Jie Wang, Rui Han, Wei Wang, Yaxin Cai, Yuqing Lv, Qianjie Chen et al. · 2020 · Theranostics
  90. New Insights into YES-Associated Protein Signaling Pathways in Hematological Malignancies: Diagnostic and Therapeutic Challenges
    Alessandro Allegra, Giovanni Pioggia, Vanessa Innao, Caterina Musolino, Sebastiano Gangemi · 2021 · Cancers
  91. Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma
    Hiromitsu Hayashi, Norio Uemura, Zhao Liu, Kazuki Matsumura, Hiroki Sato, Yuta Shiraishi, Hideo Andreas Baba · 2021 · Frontiers in Oncology
  92. Inactivation of the Hippo tumor suppressor pathway promotes melanoma
    Marc A. Vittoria, Nathan M. Kingston, Kristýna Kotýnková, Eric Xia, Rui Hong, Lee Huang, Shayna McDonald, Andrew Tilston-Lünel, Revati Darp, Joshua David Campbell et al. · 2022 · Nature Communications
  93. Direct GDP-KRAS G12C inhibitors and mechanisms of resistance: the tip of the iceberg
    Joshua C. Rosen, Adrian G. Sacher, Ming‐Sound Tsao · 2023 · Therapeutic Advances in Medical Oncology
  94. Cancer lineage-specific regulation of YAP responsive elements revealed through large-scale functional epigenomic screens
    Inês Amorim Monteiro Barbosa, Rajaraman Gopalakrishnan, Samuele Mercan, Thanos P. Mourikis, Typhaine Martin, Simon Wengert, Caibin Sheng, Fei Ji, Rui Lopes, Judith Knehr et al. · 2023 · Nature Communications
  95. Hippo vs. Crab: tissue‐specific functions of the mammalian Hippo pathway
    Miki Nishio, Tomohiko Maehama, Hiroki Goto, Keisuke Nakatani, Wakako Kato, Hirofumi Omori, Yosuke Miyachi, Hideru Togashi, Yohei Shimono, Akira Suzuki · 2017 · Genes to Cells
  96. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development
    Enrique Rozengurt, Guido Eibl · 2019 · World Journal of Gastroenterology
  97. FOXP4 Is a Direct YAP1 Target That Promotes Gastric Cancer Stemness and Drives Metastasis
    Xiaoli Liu, Bonan Chen, Fuda Xie, Kit Yee Wong, Alvin H.K. Cheung, Jinglin Zhang, Qian Ju Wu, Canbin Fang, Jintao Hu, Shouyu Wang et al. · 2024 · Cancer Research
  98. YAP1 Takes Over when Oncogenic K-Ras Slumbers
    Florian R. Greten · 2014 · Cell
  99. IL-6 increases SDCBP expression, cell proliferation, and cell invasion by activating JAK2/STAT3 in human glioma cells.
    Fang Cao, Qiang Zhang, Wei Chen, Chong Han, Yang He, Qishan Ran, Shengtao Yao · 2017 · PubMed Central
  100. Hippo-YAP signaling in digestive system tumors.
    Feng Yin, Jixin Dong, Liang‐I Kang, Xiuli Liu · 2021 · PubMed Central